Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have earned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $8.6667.

A number of brokerages have issued reports on GANX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gain Therapeutics in a report on Monday. BTIG Research reaffirmed a “buy” rating and set a $9.00 target price on shares of Gain Therapeutics in a research note on Wednesday, October 15th. Maxim Group lifted their price target on shares of Gain Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, October 7th. Roth Capital reissued a “buy” rating and set a $10.00 price objective on shares of Gain Therapeutics in a report on Friday, December 19th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research report on Friday, December 19th.

Gain Therapeutics Price Performance

Shares of Gain Therapeutics stock opened at $3.22 on Friday. The company has a market capitalization of $123.84 million, a price-to-earnings ratio of -5.28 and a beta of 0.07. The company has a quick ratio of 2.52, a current ratio of 2.52 and a debt-to-equity ratio of 0.05. The stock’s 50-day simple moving average is $2.94 and its 200-day simple moving average is $2.17. Gain Therapeutics has a 52 week low of $1.41 and a 52 week high of $4.34.

Gain Therapeutics (NASDAQ:GANX) last issued its earnings results on Wednesday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.15). As a group, analysts expect that Gain Therapeutics will post -1 earnings per share for the current fiscal year.

Institutional Trading of Gain Therapeutics

Large investors have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Gain Therapeutics during the 3rd quarter worth approximately $28,000. JPMorgan Chase & Co. bought a new stake in Gain Therapeutics in the third quarter worth $47,000. Benedict Financial Advisors Inc. raised its stake in Gain Therapeutics by 55.6% during the third quarter. Benedict Financial Advisors Inc. now owns 35,000 shares of the company’s stock valued at $62,000 after purchasing an additional 12,500 shares in the last quarter. Squarepoint Ops LLC bought a new position in Gain Therapeutics during the third quarter valued at $68,000. Finally, Virtu Financial LLC grew its stake in shares of Gain Therapeutics by 126.9% in the 3rd quarter. Virtu Financial LLC now owns 54,008 shares of the company’s stock worth $96,000 after buying an additional 30,207 shares in the last quarter. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.